Abstract
Tauopathies are neurodegenerative diseases characterized by insoluble hyperphosphorylated deposits of the microtubuleassociated protein tau in the central nervous system. In these disorders, tau is believed to cause neurodegeneration and neuronal loss due to the loss of function of the normal protein, and/or the gain of toxic properties by generating multimeric species. The obstacles found in amyloid-based therapies in Alzheimers disease, the most common tauopathy, have stimulated the search for alternative targets, including tau. In this article, we review the strategies aimed at reducing tau phosphorylation and aggregation as a target for drug intervention in tauopathies.
Keywords: Tau, tauopathies, Alzheimer, frontotemporal dementia, kinase inhibitors, dementia, immunization, Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, corticobasal syndrome, frontotemporal lobar degeneration, FTLD, post-encephalitic parkinsonism, Down syndrome, chronic traumatic encephalopathy, Niemann-Pick disease type C, postencephalitic parkinsonism, phosphorylation, glycation, glycosylation, ubiquitination, sumoylation, polyamination, nitration, nitrosylation, truncation, multiphoton microscopy, alsterpaullone, SB216763, tau fibrillization, phenothiazines, porphyrins, polyphenols, anthraquinones, phenyl thiazolylhydrazide benzofuran, pyrimidotriazines, quinoxaline, aminothienopyridazines, chloroquine, NAPVSIPQ, SMaRT technology, MMSE, AZD1080
CNS & Neurological Disorders - Drug Targets
Title: Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies
Volume: 9 Issue: 6
Author(s): Nahuai Badiola, Marc Suarez-Calvet and Alberto Lleo
Affiliation:
Keywords: Tau, tauopathies, Alzheimer, frontotemporal dementia, kinase inhibitors, dementia, immunization, Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, corticobasal syndrome, frontotemporal lobar degeneration, FTLD, post-encephalitic parkinsonism, Down syndrome, chronic traumatic encephalopathy, Niemann-Pick disease type C, postencephalitic parkinsonism, phosphorylation, glycation, glycosylation, ubiquitination, sumoylation, polyamination, nitration, nitrosylation, truncation, multiphoton microscopy, alsterpaullone, SB216763, tau fibrillization, phenothiazines, porphyrins, polyphenols, anthraquinones, phenyl thiazolylhydrazide benzofuran, pyrimidotriazines, quinoxaline, aminothienopyridazines, chloroquine, NAPVSIPQ, SMaRT technology, MMSE, AZD1080
Abstract: Tauopathies are neurodegenerative diseases characterized by insoluble hyperphosphorylated deposits of the microtubuleassociated protein tau in the central nervous system. In these disorders, tau is believed to cause neurodegeneration and neuronal loss due to the loss of function of the normal protein, and/or the gain of toxic properties by generating multimeric species. The obstacles found in amyloid-based therapies in Alzheimers disease, the most common tauopathy, have stimulated the search for alternative targets, including tau. In this article, we review the strategies aimed at reducing tau phosphorylation and aggregation as a target for drug intervention in tauopathies.
Export Options
About this article
Cite this article as:
Badiola Nahuai, Suarez-Calvet Marc and Lleo Alberto, Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237403
DOI https://dx.doi.org/10.2174/187152710793237403 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimers Disease Drug Development: Old Problems Require New Priorities
CNS & Neurological Disorders - Drug Targets Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?
Current Pharmaceutical Design Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer´s Disease
Current Neuropharmacology Didehydro-Cortistatin A Inhibits HIV-1 Tat Mediated Neuroinflammation and Prevents Potentiation of Cocaine Reward in Tat Transgenic Mice
Current HIV Research Conference Report: 6<sup>th</sup> Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Nov 14-16, 2013, The Westin San Diego Gaslamp Quarter Hotel, San Diego, CA, USA
CNS & Neurological Disorders - Drug Targets Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Amyotrophic Lateral Sclerosis: A Genetic Point of View
Current Molecular Medicine Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column
Current Pharmaceutical Design Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment
Current Alzheimer Research Bottom-Up Proteomics
Current Analytical Chemistry Subtype Classification by Polymerase and Gag Genes of HIV-1 Iranian Sequences Registered in the NCBI GenBank
Current Proteomics Neuroproteomics: Are We Biased in Our Representation of Molecular Targets Associated with Specific Domains? Implications in Biomarker Discovery
Current Proteomics Association of Cerebrospinal Fluid Adiponectin Levels With Cerebral Glucose Metabolism In Mild Cognitive Impairment: A Pilot Study
Current Alzheimer Research Density Functional Theory, Molecular Interaction Fields, Pharmacophore, Virtual Screening and Physical Chemistry of the Interactions of Novel Acetylcholinesterase Inhibitors in Alzheimer´s Disease
Current Physical Chemistry Conformationally Controlled Mechanistic Aspects of BACE 1 Inhibitors
Central Nervous System Agents in Medicinal Chemistry The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Current Topics in Medicinal Chemistry Left Anterior Temporal Glucose Metabolism and not Amyloid-beta Load Predicts Naming Impairment in Alzheimer’s Disease
Current Alzheimer Research Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses
Current Alzheimer Research